Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Amicus CEO Confident on US$1 Billion Sales Target as Japan Pompe Launch Gets Underway
As Amicus Therapeutics celebrates the Japan debut of its Pompe disease therapy, President and CEO Bradley Campbell expressed confidence that the US biotech is on track to reach US$600 million in global revenue for FY2025, up more than 10% over…
To read the full story
Related Article
- Amicus’ Pompe Disease Drugs Hit Japan Market
August 28, 2025
- Amicus to Enroll PIII Study for Pompe Therapy AT-GAA by Year-End: COO
June 10, 2019
BUSINESS
- Lilly Blasts Mounjaro Price Cut, Warns over Japan Investment Appeal
August 4, 2026
- Kyowa Kirin Profits Surge as R&D Costs Fall, Overseas Sales Grow
August 4, 2026
- Leqembi Leads US Anti-Amyloid Market; Eisai Sees Iqlik Reshaping AD Care
August 4, 2026
- Kyorin to Begin Co-Promoting Alesion Eyelid Cream on August 17
August 4, 2026
- Fujifilm, Taiho Forge Strategic Partnership on ADC Manufacturing
August 4, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…